Page 83 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Enhancers and SEs in cancer treatment

transcripts. Genome Biol. 2011;12:R113. doi: 10.1038/ng.254
doi: 10.1186/gb-2011-12-11-r113 85. Broderick P, Wang Y, Vijayakrishnan J, et al. Deciphering
the impact of common genetic variation on lung cancer
74. Kleftogiannis D, Kalnis P, Bajic VB. Progress and challenges risk: A genome-wide association study. Cancer Res.
in bioinformatics approaches for enhancer identification. 2009;69(16):6633-6641.
Brief Bioinform. 2016;17(6):967-979.
doi: 10.1158/0008-5472.CAN-09-0680
doi: 10.1093/bib/bbv101
86. Jiang Y, Jiang YY, Xie JJ, et al. Co-activation of super-
75. Wang D, Garcia-Bassets I, Benner C, et al. Reprogramming enhancer-driven CCAT1 by TP63 and SOX2 promotes
transcription by distinct classes of enhancers functionally squamous cancer progression. Nat Commun. 2018;9(1):3619.
defined by eRNA. Nature. 2011;474(7351):390-394.
doi: 10.1038/s41467-018-06081-9
doi: 10.1038/nature10006
87. Benoist C, Chambon P. In vivo sequence requirements of the
76. Li W, Notani D, Ma Q, et al. Functional roles of enhancer SV40 early promoter region. Nature. 1981;290(5804):304-310.
RNAs for oestrogen-dependent transcriptional activation.
Nature. 2013;498(7455):516-520. doi: 10.1038/290304a0
doi: 10.1038/nature12210 88. Barral A, Déjardin J. The chromatin signatures of enhancers
and their dynamic regulation. Nucleus. 2023;14(1):2160551.
77. Lee JH, Xiong F, Li W. Enhancer RNAs in cancer:
Regulation, mechanisms and therapeutic potential. RNA doi: 10.1080/19491034.2022.2160551
Biol. 2020;17(11):1550-1559. 89. Heintzman ND, Hon GC, Hawkins RD, et al. Histone
doi: 10.1080/15476286.2020.1712895 modifications at human enhancers reflect global cell-type-
specific gene expression. Nature. 2009;459(7243):108-112.
78. McCleland ML, Mesh K, Lorenzana E, et al. CCAT1 is an
enhancer-templated RNA that predicts BET sensitivity in doi: 10.1038/nature07829
colorectal cancer. J Clin Invest. 2016;126(2):639-652. 90. Ernst J, Kheradpour P, Mikkelsen TS, et al. Mapping and
doi: 10.1172/JCI83265 analysis of chromatin state dynamics in nine human cell
types. Nature. 2011;473(7345):43-49.
79. Xiang JF, Yin QF, Chen T, et al. Human colorectal cancer-
specific CCAT1-L lncRNA regulates long-range chromatin doi: 10.1038/nature09906
interactions at the MYC locus. Cell Res. 2014;24(5):513-531. 91. Nguyen TC, Cao X, Yu P, et al. Mapping RNA-RNA
doi: 10.1038/cr.2014.35 interactome and RNA structure in vivo by MARIO. Nat
Commun. 2016;7(1):12023.
80. Zhang Z, Lee JH, Ruan H, et al. Transcriptional landscape
and clinical utility of enhancer RNAs for eRNA-targeted doi: 10.1038/ncomms12023
therapy in cancer. Nat Commun. 2019;10(1):4562. 92. Hafner M, Landthaler M, Burger L, et al. Transcriptome-
doi: 10.1038/s41467-019-12543-5 wide identification of RNA-binding protein and microRNA
target sites by PAR-CLIP. Cell. 2010;141(1):129-141.
81. Jiao W, Chen Y, Song H, et al. HPSE enhancer RNA promotes
cancer progression through driving chromatin looping and doi: 10.1016/j.cell.2010.03.009
regulating hnRNPU/p300/EGR1/HPSE axis. Oncogene. 93. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-
2018;37(20):2728-2745. CLIP decodes microRNA-mRNA interaction maps. Nature.
doi: 10.1038/s41388-018-0128-0 2009;460(7254):479-486.
82. Qin N, Ma Z, Wang C, et al. Comprehensive characterization doi: 10.1038/nature08170
of functional eRNAs in lung adenocarcinoma reveals novel 94. Wu W, Yan Z, Nguyen TC, Bouman Chen Z, Chien S, Zhong S.
regulators and a prognosis-related molecular subtype. Mapping RNA-chromatin interactions by sequencing with
Theranostics. 2020;10(24):11264. iMARGI. Nat Protoc. 2019;14(11):3243-3272.
doi: 10.7150%2Fthno.47039 doi: 10.1038/s41596-019-0229-4
83. Colebatch AJ, Dobrovic A, Cooper WA. TERT gene: 95. Wen X, Luo Z, Zhao W, et al. Single-cell multiplex chromatin
Its function and dysregulation in cancer. J Clin Pathol. and RNA interactions in ageing human brain. Nature.
2019;72(4):281-284. 2024;628(8008):648-656.
doi: 10.1136/jclinpath-2018-205653 doi: 10.1038/s41586-024-07239-w
84. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer 96. Zhou B, Li X, Luo D, Lim DH, Zhou Y, Fu XD. GRID-seq
susceptibility locus at 5p15.33. Nat Genet. 2008; for comprehensive analysis of global RNA-chromatin
40(12):1404-1406. interactions. Nat Protoc. 2019;14(7):2036-2068.

Volume 7 Issue 3 (2024) 12 doi: 10.36922/itps.3654